 Diversigen, Inc., a subsidiary of OraSure Technologies Inc. OSUR, and Alimentiv Inc. formerly Robarts Clinical Trials today announced they have signed a collaboration agreement for a research study on patients with Acute Severe Ulcerative Colitis ASUC. The study, titled: Pharmacokinetics of Infliximab and Tumor Necrosis Factor Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis PROTOS Study, is designed to provide new insights into the molecular determinants of response to infliximab IFX in patients with ASUC. ASUC is the most aggressive presentation of ulcerative colitis UC, and occurs in 15 percent of adults and children with UC. 